Strategies for communicating evidence to inform decisions about health system and public health interventions

The tools developed in Work Package 5 are not limited to health systems contexts. They are for

anyone making population or individual decisions or recommendations about:

Coverage **Clinical treatments** 

Health systems or public health

## Work Package 5 **Progress and plans**

## iSoF – interactive Summary of Findings

DECIDE

Developing and Evaluating GRADE Communication strategies to support Informed Decisions and practice based on Evidence

v S Par Inte	IV vaccine for preventin Body characteristics ticipants: Girls ape 10 to 12 Invention: HPV vaccine (2 dose Noost this summary					
Ada	d or remove columns: 0		at Visual overview			
	Outcome	Pain language summary	Absolute Effect Without With HPV vaccine Nov vaccine	Relative effect (\$5% C) M droartcoarts & studies	Centainty of the evidence (DMOR)	
٣	Lifetime risk of death from cervical cancer <sup>(2)</sup>	May slightly decrease the lifetime risk of dying from cervical cancer	2 <sup>00</sup> 1 **	199 0.52 EA3 to 8.60 Eased on clear from 10000 patients in 6 studies	8800 <u>im</u> 8	
			Difference 1 less per 1000 patients (85% C) 016 1 less per 1000 patients			
			. A .			
٣	Lifetime risk of cervical cancer <sup>(2)</sup>	May slightly reduce the lifetime risk of having canvical cancer	7 <sup>10</sup> 4	<u>FIR</u> 0.52 (0-13 to 0.60) Reset envisite trave 10000	8800 MR <sup>SI</sup>	
			Difference 3 less per 1000 patients 655-Q 3 to 4 less cer 1000 patients	Based endels from 10000 patients ind studies		
			A			
٣	High grade cervical lesions (Grade 2 CIN or worse) Foto-up.15/02/ven	Probably reduces the number of central lesions with a high risk of becoming cancer (discovered by	15" 8 **	PR 0.52 (0.43 to 8.60) Besed strates from 16170 patients in5 studies	8880 102220 <sup>0</sup>	
	Training, Law a year	central screening within 1.5 to 5 years after becoming sexually	Difference 7 less per 1000 patients 855-Q 5 to 6 less cer 1000 patients			
		active)	A			
Þ	Any cervical lesion					
Þ	External genital lesions toon-	pr 1.5 to 5 years				
	Serious adverse effects stores: 15 to 2 mm					

is to help groups of people (panels) making healthcare The purpose of iSoF is to help people understand key messages from a

- systematic review, including: The most important outcomes (both benefits and harms)
- Size of these effects
- Certainty of this evidence

We are developing and testing the iSoF functionality and formatting with a wide range of stakeholders and end users. We will be carrying out trials to test understanding and usefulness compared with paper SoF tables.

nuary 2011 oject start	December 2012 Design of iSoF	March 2013 iSoF version 1		December 2014 iSoF version 3	December 2015 - Project finish
	Based on: Paper version of SoF, brainstorming, feedback, user testing of paper sketches	Based on Brainstorming stakeholder feedback programming limitations/opportunitie	, User testing, , feedback, brainstorming	Based on: user testing, real-life application, stakeholder feedback,trials	September 2015 iSoF integrated in GDT (Gidefine Development Tool)
1	2011	2012	2013	2014	2015

## iEtD – interactive Evidence to Decision Framework



Pro

## GET IT – Glossary of Evaluation Terms for Informed Treatment choices in plain language



We are developing a glossary of terms that people may need to understand to make sense of evidence-based information for treatment choices. The work is based on a thorough review of existing glossaries. We will be evaluating the content in multiple ways and collaborating with potential end-user organisations when developing functionality and formatting. We anticipate that the glossary will be available in several languages.





This project has received funding from the European Union's Seventh Framework Programme for research, technological development and demonstration under grant agreement no 258583.

